When loss of function mutations of Tp53 were combined with Kras oncogenic mutations, late-stage disease progression of lung adenocarcinoma was observed; nuclear atypia, elicit stromal desmoplasia, invasion, and metastasis (Jackson et al., 2005). This evidence concerns the gene KRAS and lung adenocarcinoma.